{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-038211","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.311692+00:00","generated_at":"2026-05-16T12:43:15.497844+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DiaMedica provides DM199 preeclampsia update after FDA pre-IND meeting; additional rabbit study required","bullets":["FDA requested one non-clinical 10-day rabbit EFD/PPND study; results expected by Q2 2026.","Phase 2 investigator-sponsored trial in South Africa has dosed over 30 women with late-stage PE.","Interim data: statistically significant blood pressure reductions, uterine artery dilation, no placental transfer.","Regulatory clarity obtained for IND submission to study DM199 in early-onset preeclampsia."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-038211","json":"https://secwatch.observer/filing/0001437749-25-038211.json","markdown":"https://secwatch.observer/filing/0001437749-25-038211.md","text":"https://secwatch.observer/filing/0001437749-25-038211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925038211/0001437749-25-038211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925038211/dmtp20251217_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:43:15.497844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}